Translational studies to test potential therapies for patients with primary biliary cirrhosis
MASON, Andrew L
5 records totalling $2,554,348.00 CAD, from official Government of Canada open data.
Embed this chart
By department
| Canadian Institutes of Health Research | $2,554,348 | 5 records |
Records
MASON, Andrew L
$768,058.00
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada
FY 2014-2015
Canada
Mason, Andrew L
$703,800.00
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada
FY 2018-2019
Canada
Pilot study of emtricitabine, tenofovir alafenamide and raltegravir for patients with primary biliary cholangitis
MASON, Andrew L
$506,269.00
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada
FY 2011-2012
Canada
Pilot study of highly active anti-retroviral therapy for patients with primary biliary cirrhosis
MASON, Andrew L
$426,221.00
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada
FY 2011-2012
Canada
Isolation of a novel human retrovirus associated with primary biliary cirrhosis and fulfillment of koch's postulates in vitro
Mason, Andrew L
$150,000.00
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada
Research in Priority Areas
FY 2020-2021
Canada
The specific objective of this funding opportunity is: To harness the power of new technologies and interventions to prevent the onset of cancer and/or reduce its severity though early detection wh...